Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference

GlobeNewswire September 29, 2020

Akari Therapeutics to Participate in Two September Virtual Investor Conferences

GlobeNewswire September 10, 2020

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire September 1, 2020

Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

GlobeNewswire August 31, 2020

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

GlobeNewswire August 12, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

GlobeNewswire July 1, 2020

Akari Therapeutics Announces Appointment of Chief Financial Officer

GlobeNewswire July 1, 2020

Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire May 29, 2020

Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

GlobeNewswire May 21, 2020

Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series

GlobeNewswire May 4, 2020

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

GlobeNewswire May 1, 2020

Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

GlobeNewswire March 31, 2020

Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

GlobeNewswire March 4, 2020

Akari Therapeutics, Plc Announces Private Placement

GlobeNewswire February 20, 2020

Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

GlobeNewswire January 27, 2020

Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study

GlobeNewswire January 10, 2020

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND

GlobeNewswire December 23, 2019

Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

GlobeNewswire December 2, 2019

Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress

GlobeNewswire November 4, 2019

Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

GlobeNewswire October 14, 2019